Loading clinical trials...

COPD Circuit Exercise | Clinical Trials | Clareo Health

COMPLETEDNA

COPD Circuit Exercise

Circuit-Exercise Training on Subjects With and Without Chronic Respiratory Disease

NCT05395390•Texas A&M University

Summary

This study is being done to understand body's response to hybrid home-based and on-site rehabilitation program utilizing individually tailored exercises throughout a total of 18 sessions with 12 of them occurring onsite, in people with and without chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA) and in individuals recovered from COVID-19. Exercise training programs vary widely for people with COPD, OSA, and during prolonged recovery from COVID infection. This study will help identify if this program is helpful to address muscle loss and fatigue specifically in populations with and without chronic respiratory diseases.

Eligibility

Age

30 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Ability to walk, sit down and stand up independently
•* Age 30 - 85 years
•* Ability to lay in supine or elevated position for up to 3 hours
•* Diagnosis of moderate to very severe chronic airflow limitation and compliant to the following criteria: FEV1 \< 70% of reference FEV1
•or- Obstructive Sleep Apnea (OSA)
•or- 2 weeks post-recovered\* from laboratory confirmed case of COVID
•● Willingness and ability to comply with the protocol
•\*Recovered is defined according to Brazos County Health District as someone who has been fever-free for 24 hours without fever-reducing medications, and it has been 10 days after onset of symptoms.
•Healthy male or female according to the investigator's or appointed staff's judgment
•Ability to walk, sit down and stand up independently
+4 more criteria

Exclusion Criteria

•Unable to exercise due to physical limitations (i.e. neuromuscular and/or orthopedic disorders)
•* Established diagnosis of malignancy
•* Presence of acute illness or metabolically unstable chronic illness
•* Presence of fever within the last 3 days.
•* Expected to have surgery within 1 month of screening or during exercise training
•* Any other condition according to the PI or research staff that was found during the screening visit, that would interfere with the study or safety of the patient.
•* Previous injury that could interfere with participation in resistance exercise protocol.
•* Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.
•* (Possible) pregnancy.

Locations (1)

Texas A&M University

College Station, Texas, United States

Key Dates

Start Date

February 2, 2021

Primary Completion Date

August 7, 2023

Completion Date

August 7, 2023

Last Updated

September 30, 2025

Enrollment

ACTUAL participants

Conditions

OSACovid19Residual Symptoms of COVID 19COPD

Interventions

Exercise (Resistance Training

BEHAVIORAL

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

COPD Circuit Exercise

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

Cognitive Evaluation of Patients With Eating Disorders

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Digital-supported Orofacial Myofunctional Therapy in OSA